Par Pharmaceutical: Providing Patients and Customers with Uncompromising Quality and Value for More than 30 Years

Generic SupplementsGeneric Supplement 2013

Since 1978, Par Pharmaceutical has been at the forefront of developing, manufacturing, marketing and distributing safe, innovative and costeffective pharmaceuticals that help improve patient quality of life. Every week in America, more than one million Par prescriptions are dispensed. In return for the trust that is placed in us, we are committed to providing products of uncompromising quality. In fulfilling this mission, we deliver value to our customers and the physicians and patients that rely on us. Today, the company’s sales place it among the top 5 largest generic pharmaceutical companies in the United States. Par manufactures, licenses and markets almost 70 products.

A Partner to Rely On

At Par, our most important resource is the talent and dedication of our 900 employees, each of whom is part of a culture that values integrity, customer focus, teamwork, and performance. Headquartered in Woodcliff Lake, New Jersey, Par has manufacturing and R&D facilities in Spring Valley, New York, Irvine, California and Chennai, India.

Par Pharmaceutical's facility in Spring Valley, New York.

Promising Product Pipeline

Since the beginning of 2012, Par has launched almost 20 new products, while filing about two dozen abbreviated new drug applications. Par possesses one of the most promising new product pipelines in the generic drug industry, with 77 products awaiting FDA approval, including as many as 30 f irst-to-files, and more than 80 other products in development. In recent years, the company has introduced generic versions of several major pharmaceutical products, including modafinil, rizatriptan, lamotrigine ER, metoprolol succinate, tramadol ER, propafenone ER and budesonide. Large enough to maintain a significant trade presence, yet agile enough to provide maximum attention to customers, Par remains poised to continue its impressive track record of success.

Recent Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs